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Survival rates in breast cancer continue to increase in most
Western countries. This is undoubtedly underpinned in part
by advances in breast cancer therapy and a wider range of
treatments. Better surgical techniques and chemotherapeutic
regimens, and more specific and potent targeted treatment
have all combined to increase therapeutic efficacy while
reducing morbidity in the general population of patients with
breast cancer. Nevertheless, not all patients experience
benefit. Tumours that respond to one form of treatment fail to
respond to therapies that are effective in other breast
cancers. Similarly, a treatment that overall might produce
lower responses can still be extremely effective in a subset of
breast cancer patients. Ideally, optimal management would
offer the most effective treatment on an individual basis.
Improving the tailoring or personalization of treatment,
founded upon patient and tumour characteristics, is therefore
a major objective of clinical practice and translational
research. The current status of personalized treatment was
the topic of two meeting sessions.
Professor Monica Morrow [1] considered surgical treatment.
She reviewed changes in surgical practice that have occurred
since the 1940s, selection criteria for breast-conserving
treatment, the need for radiotherapy and individualized
management of the axilla (focusing on the role of sentinel node
biopsy). Surgery is the first treatment modality faced by the
majority of patients. Tailoring surgical therapy is based largely
on patient choice along with consideration of a number of
mechanical/cosmetic issues that pertain to the size and
location of the lesion. However, molecular predictors of risk for
both local and systemic spread were identified as particular
future needs; markers that indicate that the no surgery option
was safe for the elderly/unfit would also be helpful.
Postsurgical radiotherapy is currently under greater study in
relation to molecular predictability, but this relates at least as
much to predicting normal tissue damage as to the antitumour
efficacy of the treatment.
Professor Mitch Dowsett and colleagues [2] addressed the
topic of ‘short-term preoperative treatment for all’, in which
the approach is to use the interval between time of diagnosis
and surgery to employ treatment, and to measure the effect
on proliferation and/or other molecular markers in tumour
biopsies. They identified advantages in terms of being able to
identify on-treatment prognostic indices and biological
responses that might be used to select subsequent adjuvant
therapy. Conversely, there could be potential disadvantages
relating to long-term detrimental effects, downgrading of
disease (currently used to select treatment), and the extra
workload for surgeons and pathologists (when equivalent
information might be derived from pretreatment samples). The
potential of presurgical treatment was illustrated by
comparing results from the IMPACT (Immediate Preoperative
Anastrozole Tamoxifen or Combined with Tamoxifen) and
ATAC (Arimidex, Tamoxifen Alone or Combination) trials.
Thus, the information from short-term neoadjuvant treatment
in the IMPACT trial (involving hundreds of patients) would
have predicted the results of long-term treatment in the ATAC
adjuvant trial (involving thousands of patients). These results
have provided the impetus for the POETIC (PeriOperative
Endocrine Treatment for Individualising Care) prospective
clinical trial, in which results from presurgical treatment are
being used to stratify subsequent adjuvant therapy.
The topic covered by Professor Per Lonning [3] was ‘the
contribution of expression microarrays in personalizing
adjuvant treatment’. He provocatively indicated that micro-
arrays have yielded no advances in personalizing adjuvant
treatment and that it will be a long time before they do so.
This is because of wrong conceptual use. The need to apply
technology and bioinformatics to biology rather than
moulding observations to fit in with bioinformatic models was
emphasized. However, there was hope in that we now have
the tools with which to elucidate key mechanisms of cancer
development and therapy. Furthermore, gene expression
patterns from microarrays are providing useful tumour
subclassification, most notably Oncotype Dx™ (Genomic
Health Inc., Redwood City, CA, USA) and the MammaPrint
(Agendia BV, Amsterdam, The Netherlands). Each of these is
being tested in a large prospective clinical trial (TAILORx
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[Trial Assigning IndividuaLized Options for Treatment] and
MINDACT [Microarray for Node-Negative Disease may Avoid
Chemotherapy], respectively) to assess how much clinical
benefit is derived from their application.
Professor Matt Ellis [4] considered progress made in
personalized endocrine treatment. He identified the
therapeutic choices available and key issues such as
prediction of response, the role of neoadjuvant therapy as a
test bed for adjuvant treatment, and combination of endocrine
therapy with other signal transduction inhibitors. In terms of
response prediction, the status of proliferation markers and
cerbB2 were evaluated as illustrative examples using findings
from trials comparing aromatase inhibitors with tamoxifen.
The potential of using endocrine therapy with drugs that
influence phosphoinositol-3-kinase (PI3K) signalling was also
highlighted. A major point from the presentation and a
recurrent theme from other topics in the session was that
studies conducted in the neoadjuvant setting would be
particularly informative in validating translation research and
progressing preliminary clinical observations toward the
ultimate goal of personalizing treatment.
There is no doubt that substantial effort will be made to
improve personalized therapy. The challenge of patients who
respond to treatments that do not benefit the majority and
vice versa must still be faced. However, with greater
emphasis on targeted therapy and the ability to measure the
target, tailored treatment may become rational and more
easily achieved.
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